AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12390563 — intervention group
Group type: EXPERIMENTAL
Intervention: Option‐4 algorithm (O‐4)
Number of subjects: 16
Study 12390563 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Option‐4 algorithm (MO‐4)
Number of subjects: 16
Study 12390563 — intervention group
Group type: EXPERIMENTAL
Intervention: Option‐3 method (O‐3)
Number of subjects: 16
Study 12390563 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Pass method (DP)
Number of subjects: 16
Study 9895342 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine therapy (11, 22, and 44 mg daily)
Number of subjects: 71
Study 7769051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin 200 micrograms twice daily
Number of subjects: 240
Study 7769051 — intervention group
Group type: COMPARATOR
Intervention: Buserelin 200 micrograms five times daily
Number of subjects: 240
Study 7769051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin 400 micrograms twice daily
Number of subjects: 240
Study 7769051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin 200 micrograms
Number of subjects: 240
Study 7769051 — intervention group
Group type: COMPARATOR
Intervention: Buserelin
Number of subjects: 240
Study 7769051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (either dose)
Number of subjects: 240
Study 2126222 — intervention group
Group type: EXPERIMENTAL
Intervention: ibopamine-captopril
Number of subjects: 23
Study 2126222 — intervention group
Group type: COMPARATOR
Intervention: ibopamine-placebo
Number of subjects: 23
Study 2126222 — intervention group
Group type: COMPARATOR
Intervention: captopril-placebo
Number of subjects: 23
Study 2126222 — intervention group
Group type: COMPARATOR
Intervention: placebo-placebo
Number of subjects: 23
Study 282999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (20 g of chocolate with sorbitol)
Number of subjects: 0
Study 282999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (20 g of chocolate with 40% sucrose)
Number of subjects: 0
Study 282999 — intervention group
Group type: COMPARATOR
Intervention: Control group (children living in Budapest)
Number of subjects: 0
Study 28900715 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 250
Study 28900715 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 250
Study 28900715 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) and Transfemoral access (TFA)
Number of subjects: 250
Study 27857015 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based preconception health promotion program (6-hour lecture series over 4 weeks)
Number of subjects: 51
Study 24094613 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site group cognitive behavioral therapy (CBT) for depression
Number of subjects: 0
Study 24094613 — intervention group
Group type: COMPARATOR
Intervention: Usual care residential treatment
Number of subjects: 0
Study 23739435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavinton (25 mg intravenous during 10 days and then 10 mg 3 times daily during 3 months)
Number of subjects: 180
Study 20837089 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser fluorescence measurements for sound sites (D(0), n=40)
Number of subjects: 117
Study 20837089 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser fluorescence measurements for D(0-2) (n=74)
Number of subjects: 117
Study 20837089 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser fluorescence values for opened lesions (n=43)
Number of subjects: 117
Study 18415093 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (4 mg/kg)
Number of subjects: 15
Study 18415093 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (10 mg/kg)
Number of subjects: 15
Study 18415093 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Artesunate and Amodiaquine
Number of subjects: 15
Study 16192502 — intervention group
Group type: EXPERIMENTAL
Intervention: MV with Vt = 10 mL/kg
Number of subjects: 32
Study 16192502 — intervention group
Group type: COMPARATOR
Intervention: MV with Vt = 5 mL/kg
Number of subjects: 32
Study 12621632 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg/day
Number of subjects: 21
Study 12621632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 12621632 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 21
Study 10856673 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin 1 g every 12 hours
Number of subjects: 0
Study 10856673 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin 1 g every 24 hours
Number of subjects: 0
Study 9118847 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with childhood-onset epilepsy
Number of subjects: 176
Study 9118847 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 176
Study 9118847 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving AED polytherapy
Number of subjects: 176
Study 9118847 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving AED monotherapy
Number of subjects: 176
Study 9118847 — intervention group
Group type: EXPERIMENTAL
Intervention: Current AED therapy
Number of subjects: 176
Study 8455969 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 514
Study 8455969 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-TENS
Number of subjects: 514
Study 8455969 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 514
Study 3541427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (two doses: one at birth and another 2 months later, plus a booster at 12 months)
Number of subjects: 0
Study 3541427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (booster dose at 12 months)
Number of subjects: 0
Study 3541427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (two doses)
Number of subjects: 0
Study 3541427 — intervention group
Group type: COMPARATOR
Intervention: Nonimmunized newborns
Number of subjects: 0
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 3 mg
Number of subjects: 79
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 10 mg
Number of subjects: 79
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 30 mg
Number of subjects: 79
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg
Number of subjects: 79
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg
Number of subjects: 79
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 400 mg
Number of subjects: 79
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 800 mg
Number of subjects: 79
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 30 mg QD for 10 days
Number of subjects: 79
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg QD for 10 days
Number of subjects: 79
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg QD for 10 days
Number of subjects: 79
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 400 mg QD for 10 days
Number of subjects: 79
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg BID for 10 days
Number of subjects: 79
Study 29672897 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg BID for 10 days
Number of subjects: 79
Study 29672897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 26035523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 to 450 mg/d)
Number of subjects: 119
Study 26035523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 26995811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) integrated with dental treatment
Number of subjects: 55
Study 26995811 — intervention group
Group type: COMPARATOR
Intervention: Adapted dental treatment
Number of subjects: 55
Study 22999067 — intervention group
Group type: EXPERIMENTAL
Intervention: ETT size 6.0 with lidocaine (Group D)
Number of subjects: 240
Study 22999067 — intervention group
Group type: COMPARATOR
Intervention: ETT size 7.0 with saline (Group A)
Number of subjects: 240
Study 22999067 — intervention group
Group type: COMPARATOR
Intervention: ETT size 6.0 with saline (Group B)
Number of subjects: 240
Study 22999067 — intervention group
Group type: COMPARATOR
Intervention: ETT size 7.0 with lidocaine (Group C)
Number of subjects: 240
Study 20593634 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline microspheres plus scaling and root planing
Number of subjects: 127
Study 20593634 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 127
Study 18794556 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 380
Study 18794556 — intervention group
Group type: COMPARATOR
Intervention: Simple touch (control)
Number of subjects: 380
Study 18794556 — intervention group
Group type: COMPARATOR
Intervention: Both groups (massage and control)
Number of subjects: 380
Study 15752945 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan low-dose (2.5/5.0 mg)
Number of subjects: 175
Study 15752945 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan middle-dose (25/50 mg)
Number of subjects: 175
Study 15752945 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan high-dose (50/100 mg)
Number of subjects: 175
Study 15752945 — intervention group
Group type: COMPARATOR
Intervention: Switch from middle-dose losartan to placebo
Number of subjects: 175
Study 15752945 — intervention group
Group type: COMPARATOR
Intervention: Switch from high-dose losartan to placebo
Number of subjects: 175
Study 15752945 — intervention group
Group type: COMPARATOR
Intervention: Switch from low-dose losartan to placebo
Number of subjects: 175
Study 11919526 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron
Number of subjects: 145
Study 11919526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 10375429 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastoviscous 0.1% Hylan A solution
Number of subjects: 0
Study 10375429 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Number of subjects: 0
Study 10375429 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 8884589 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist community service 1
Number of subjects: 0
Study 8884589 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist community service 2
Number of subjects: 0
Study 8884589 — intervention group
Group type: COMPARATOR
Intervention: Non-referred sample
Number of subjects: 0
Study 8884589 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff morale
Number of subjects: 0
Study 1464864 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (3.8 g of eicosapentaenoic acid plus 2.0 g of docosahexaenoic acid) and naproxen (750 mg/day for 16 weeks)
Number of subjects: 67
Study 1464864 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (as Group 2) and naproxen (as Group 1)
Number of subjects: 67
Study 1464864 — intervention group
Group type: COMPARATOR
Intervention: corn oil (placebo omega-3 fatty acids, 7 g/day for 16 weeks) and naproxen (750 mg/day for 10 weeks followed by stepwise reduction)
Number of subjects: 67
Study 6498042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed p.v.c. tracheal tubes
Number of subjects: 80
Study 6498042 — intervention group
Group type: EXPERIMENTAL
Intervention: Red rubber tracheal tubes
Number of subjects: 80
Study 6498042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent adjustment of cuff volume
Number of subjects: 80
Study 6498042 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidification of inspired gases
Number of subjects: 80
Study 6498042 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetists unaware of the trial
Number of subjects: 80
Study 6498042 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 80
Study 29734211 — intervention group
Group type: EXPERIMENTAL
Intervention: Early colonoscopy (<24 hours)
Number of subjects: 132
Study 29734211 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (1 to 3 days)
Number of subjects: 132
Study 29734211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 132
Study 29277856 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-irinotecan (HA-IR) + Carboplatin (C)
Number of subjects: 34
Study 29277856 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan (IR) + Carboplatin (C)
Number of subjects: 34
Study 27854314 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (150 mg polyphenols)
Number of subjects: 19
Study 27854314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23601079 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional radiofrequency ablation (RFCA) for spontaneous dissociated pulmonary vein activity (DPV‐spike) after pulmonary vein isolation (PVI)
Number of subjects: 152
Study 23601079 — intervention group
Group type: COMPARATOR
Intervention: Only pulmonary vein isolation (PVI)
Number of subjects: 152
Study 21742098 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Fontan coil embolization of APCs
Number of subjects: 539
Study 21742098 — intervention group
Group type: COMPARATOR
Intervention: No pre-Fontan coil embolization of APCs
Number of subjects: 539
Study 19130903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation
Number of subjects: 0
Study 19130903 — intervention group
Group type: COMPARATOR
Intervention: Uterosacral vaginal vault suspension
Number of subjects: 0
Study 19130903 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral techniques and pelvic floor muscle training
Number of subjects: 0
Study 19130903 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16739841 — intervention group
Group type: EXPERIMENTAL
Intervention: Local single-point electroacupuncture stimulation
Number of subjects: 98
Study 16739841 — intervention group
Group type: COMPARATOR
Intervention: Routine electroacupuncture stimulation
Number of subjects: 98
Study 15001605 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily (group 1)
Number of subjects: 37
Study 15001605 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg twice weekly (group 2)
Number of subjects: 37
Study 15001605 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily (group 3)
Number of subjects: 37
Study 11709513 — intervention group
Group type: COMPARATOR
Intervention: Low LCT feed
Number of subjects: 54
Study 11709513 — intervention group
Group type: EXPERIMENTAL
Intervention: High LCT feed
Number of subjects: 54
Study 9406002 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (Group 1)
Number of subjects: 23
Study 9406002 — intervention group
Group type: COMPARATOR
Intervention: Visual laser ablation of the prostate (Group 2)
Number of subjects: 23
Study 12959308 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroximone (0.5 mg kg(‐1); n = 10)
Number of subjects: 30
Study 12959308 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 mg kg(‐1); n = 10)
Number of subjects: 30
Study 12959308 — intervention group
Group type: COMPARATOR
Intervention: Control (NaCl as placebo; n = 10)
Number of subjects: 30
Study 12959308 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroximone and Enoximone
Number of subjects: 30
Study 2885116 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg daily
Number of subjects: 64
Study 2885116 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 64
Study 2885116 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordesmethyldiazepam 2 mg daily
Number of subjects: 64
Study 2885116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 30824268 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil (CB)
Number of subjects: 16
Study 30824268 — intervention group
Group type: COMPARATOR
Intervention: Butter (BB)
Number of subjects: 16
Study 30824268 — intervention group
Group type: COMPARATOR
Intervention: Lard (LB)
Number of subjects: 16
Study 30139892 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling sessions
Number of subjects: 168
Study 27044017 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive school-based program (peer-performed play and school lessons)
Number of subjects: 815
Study 27044017 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 815
Study 25234550 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg test tablet
Number of subjects: 36
Study 25234550 — intervention group
Group type: COMPARATOR
Intervention: Reference tablet
Number of subjects: 36
Study 25234550 — intervention group
Group type: EXPERIMENTAL
Intervention: Test tablet
Number of subjects: 36
Study 25234550 — intervention group
Group type: COMPARATOR
Intervention: Reference Supplemental Table II
Number of subjects: 36
Study 23800419 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (targeted dose adjusted to 200-300 ng/ml)
Number of subjects: 85
Study 23800419 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (high-dose, increased to 300-375 mg/day)
Number of subjects: 85
Study 23800419 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (in subgroup without psychotic features)
Number of subjects: 85
Study 23800419 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (in subgroup without psychotic features)
Number of subjects: 85
Study 20142540 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (shorter acclimatization time)
Number of subjects: 28
Study 20142540 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (longer acclimatization time)
Number of subjects: 28
Study 20142540 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 18401987 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia using intravenous or inhaled anesthesia, maintenance with sevoflurane in oxygen and air at variable concentrations to maintain a bispectral index (BIS) between 40 and 60.
Number of subjects: 47
Study 18401987 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia in patients with severe to very severe mental disability.
Number of subjects: 47
Study 18401987 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia in patients with mild to moderate mental disability.
Number of subjects: 47
Study 18401987 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring during anesthesia.
Number of subjects: 47
Study 18401987 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic technique used in the study.
Number of subjects: 47
Study 19907420 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg of the ampakine CX717
Number of subjects: 16
Study 19907420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19907420 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg of naloxone
Number of subjects: 16
Study 16358864 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (cefuroxime axetil, clarithromycin) and steroid (prednisone)
Number of subjects: 116
Study 16358864 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics (cefuroxime axetil, clarithromycin)
Number of subjects: 116
Study 12148574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide by a 24-hour infusion on day 1
Number of subjects: 30
Study 12148574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide by a 3-hour infusion on days 1-4
Number of subjects: 30
Study 9548630 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management and peer support
Number of subjects: 0
Study 9548630 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group
Number of subjects: 0
Study 8307444 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg or 40 mg) for 5.7 weeks
Number of subjects: 25
Study 8307444 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prior antisecretory treatment)
Number of subjects: 25
Study 8307444 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg or 40 mg)
Number of subjects: 25
Study 3144207 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-based diet (CB, 53% carbohydrate)
Number of subjects: 16
Study 3144207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-based diet (FB, 55% fat)
Number of subjects: 16
Study 3144207 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (D5W) infusion
Number of subjects: 16
Study 11774069 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional instability of the ankle (14 subjects)
Number of subjects: 24
Study 11774069 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (10 subjects)
Number of subjects: 24
Study 29726013 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Remote Ischemic Conditioning (CORIC) consisting of per-RIC, post-RIC, and delayed RIC
Number of subjects: 200
Study 29726013 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 200
Study 29726013 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Remote Ischemic Conditioning (CORIC)
Number of subjects: 200
Study 25924098 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS with positive expectations
Number of subjects: 161
Study 25924098 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS with neutral expectations
Number of subjects: 161
Study 25924098 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS with negative expectations
Number of subjects: 161
Study 25924098 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS with positive expectations
Number of subjects: 161
Study 25924098 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS with neutral expectations
Number of subjects: 161
Study 25924098 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS with negative expectations
Number of subjects: 161
Study 24906579 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic Training (AT)
Number of subjects: 66
Study 24906579 — intervention group
Group type: COMPARATOR
Intervention: Control group (Physiotherapy alone)
Number of subjects: 66